logo
LSE:GNS logo

Genus Community

LSE:GNS Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

GNS logo
Genus
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts

FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream

Key Takeaways Growth in the porcine division and strategic partnerships in China are expected to enhance Genus's revenue and earnings. Expansion in the bovine segment through acquisitions and programs like VAP is projected to improve profit margins and financial stability.
View narrative
UK£24.58
FV
14.8% undervalued intrinsic discount
4.03%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
1 day ago author updated this narrative